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of treatment. Patients treated with TUR-B followed by 
radiotherapy were significantly older compared to patients 
with cystectomy before radiotherapy and were less likely to 
receive chemotherapy. There was no significant difference 
for the length of the interval between first treatment and 
radiotherapy for the three groups. Despite of this, type of 
surgical procedure before radiotherapy did not show an 
impact on overall survival (p = 0.86). 
 
Conclusion: In our study we found equal survival of patients 
treated with (chemo)radiotherapy after TUR-B only compared 
to patients with cystectomy prior to radiotherapy. Younger 
age and more concomitant chemotherapy of the latter group 
was not able to prolong survival.  
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Purpose or Objective: In cancers of the head and neck 
(HNCa), lymph node (LN) status is a critical prognostic factor. 
Further, the presence of extracapsular extension (ECE) has 
been shown prospectively to be a criterion for the addition of 
chemotherapy to postoperative radiation therapy. Limited 
data exist regarding ECE in inguinal or pelvic LNs from 
primary penile cancer (PeCa). 
 
Material and Methods: We retrospectively analyzed 
outcomes of patients with PeCa and pathologically confirmed 
LN across four international tertiary referral centers. Clinical 
and demographic characteristics were compared of outcomes 
(local control and overall survival) by ECE status and between 
those who had received adjuvant RT or not. 
 
Results: Records of 93 patients were available. Median age at 
time of LND was 65.3 years (range 35.9–90.2 years). Median 
follow up was 9.4 months (IQR: 5.3-19.4). The median 
number of involved ILNs was 4 (range 1-12), and median PLNs 
positive was 2 (range 1-21). 72% of patients had ECE in the 
inguinal area and 49% had ECE in the pelvis. Infield failure 
occurred in 26/87 sites with ECE and 8/64 sites without ECE 
(p = 0.015). In the presence of ECE, patients receiving RT 
experienced infield failure in 17/50 cases and in 10/38 
patients not receiving RT (P=NS). Absent ECE, patients failed 
infield in 5/40 cases after RT and 3/24 cases without RT 
(p=NS). RT was not associated with improved OS (p=0.073) or 
recurrence (p=0.492) on multivariate analysis. Chemotherapy 
was significant on multivariate analysis for recurrence (p = 
0.009) but not survival (p=0.334). 
 
Conclusion: ECE is associated with increased likelihood of 
local recurrence in PeCa patients. Contrary to the experience 
in HNCa, adjuvant RT has no impact on local control. 
Prospective studies are needed to validate this unusual 
finding and further develop the timing and roles of RT and 
chemotherapy for PeCa patients with advanced disease. 
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Purpose or Objective: the aim of this study was the 
evaluation of local control (LC) and toxicity in 
oligometastatic patients with renal cell carcinoma (RCC) who 
had undergone stereotactic radiotherapy (SRT) with 
CyberKnife (Accuray, Sunnyvale, CA) or Vero™ (BrainLab) for 
cranial and extracranial metastases. 
 
Material and Methods: between January 2012 and September 
2015, 23 patients (30 lesions) with metastases of RCC were 
treated with SRT alone to the new site of disease (if limited 
disease) or to residual disease during the maximal response in 
systemic therapy. Disease control was evaluated with serial 
imaging. Toxicity was recorder according to the Common 
Toxicity Criteria version 4.0. 
 
Results: after a median follow-up of 10 months (range 0 - 36 
months) 20 patients were alive. Ten patients received SRT 
alone and 13 patients received that during the maximal 
response of systemic therapy. The median equivalent of the 
dose (EQD2) was 50.6 Gy delivered with a median of 2.7 
fractions (range 1-5) and the median biological equivalent 
dose (BED) was 51 Gy assuming α/β =10 for tumour. Six 
patients are lost in follow-up. Clinical and radiological 
response was thus evaluated in 17 patients and the their LC 
was 100% (57.1% of patients received SRT alone and the 
others patients are still undergoing systemic treatment. 
27.7% of patients had more than 12 months follow-up and the 
LC was again 100%. ). Progression of disease in the other sites 
was observed in all cases. No toxicity was observed. 
 
Conclusion: SRT is a feasible approach that offer an 
excellent LC with low toxicity profile in the treatment 
management of oligometastatic patients with RCC with or 
without the association of systemic therapy. Further 
investigation is warranted to identify the patients who would 
probably benefit from this approach. 
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Purpose or Objective: Acute urinary unwished effects of 
pelvic irradiation may impact on quality of life of patients 
undergoing radiation therapy on the pelvis. Neoplasms such 
endometrial, cervical, rectal, and anal cancer requires 
irradiation of relevant pelvic volumes. In this study we tested 
Cystoman, a dietary integrator of D-mannosium, cranberry 
and vitamin C, as prophylactic therapy for the development 
of acute urinary side effects. 
 
Material and Methods: Fifty five patients undergoing pelvic 
irradiation were randomly assigned to take 2 tablets/day of 
Cystomann or not from the beginning of radiation therapy. 
Radiation therapy consisted of 45 - 50.4 Gy on the pelvis 
given by 1.8 Gy daily fractions with 3D conformal radiation 
therapy. The patients were weekly checked for urinary 
symptoms. Urine colture was performed before and after the 
treatment. 
 
Results: Between November 2014 and September 2015, 55 
consecutive patients were enrolled in the study. Median age 
was 65 year, 11 were affected by cervical cancer, 9 
endometrial, 31 rectal, and 4 anal cancer. Twenty two 
patients were treated preoperatively and 33 postoperatively. 
Urinary toxicity appeared at the second week in 3/28 
patients in Cystoman group and 11/27 in the control group 
(p=0,02). However by the end of the treatment 8/28 and 
13/27 patients had urinary toxicity in the Cystoman and 
control group, respectively (p=0.1). 
 
Conclusion: Our study suggests that Cystomann delays the 
radio-induced acute urinary toxicity presentation and could 
ameliorate the toxicity profile of the pelvic irradiation. 
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Purpose or Objective: Description of three cases of total 
skin irradiation for cutaneous T-cell lymphoma using helical 
TomoTherapy (Accuray, Sunnyvale, CA). 
 
Material and Methods: In 2015, three patients with 
refractory T-cell lymphoma underwent total skin irradiation 
using invers-planned helical tomotherapy. The first case was 
a 25-year-old man diagnosed as mycosis fungoides with 
multiple tumors occurring on the extremities, face, and 
trunk. The second case was a 73-year-old woman diagnosed 
as primary cutaneous gamma delta T-cell lymphoma. She had 
received 24 Gy of irradiation in 12 fractions with total skin 
electron beam irradiation technique 10 years ago, and some 
parts of her skin were irradiated with 24 Gy in 12 fractions 
with local electron beam irradiation within 3 years. The third 
case was a 52-year-old man diagnosed as mycosis fungoides. 
No bolus was added around the body. Because of the long 
length of treatment of the body in TomoTherapy, treatments 
were delivered to three parts of the body (trunk, head and 
neck, and legs). Irradiation was not performed in two or 
three parts on the same day. Each plan was generated with a 
prescription dose of 10 Gy in 10 fractions. The planning 
target volume (PTV) was the body surface with 5mm margins 
of internal and external lesions of the skin. The third patient 
had several swelling lymph nodes, so the PTV was the body 
surface and swelled lymph nodes with their margins. 
 
Results: TomoTherapy technique was created that enabled 
delivery of the prescription dose to PTV with a relatively 
sharp drop-off of dose at depth. The calculated mean doses 
for the organs at risk were 1.96, 2.08, 2.12, 2.19, and 2.27 
Gy for the lung, heart, liver, kidneys, and bones, 
respectively. Using the couch-indexed Vac-Lok cushion and 
head mask, inter- and intra-fractional patients motions were 
minimized. All three patients experienced edemas of fingers 
and toes, and lost much of their hair. Myelosuppression 
occurred in two of the three patients. Because of grade 4 
myelosuppression, the second patient who was treated total 
skin electron beam irradiation 10 years ago, was treated with 
blood transfusion during the treatment. All tumors were 
reduced during and after the treatment. 
 
Conclusion: Using the TomoTherapy technique in total skin 
irradiation, we were able to achieve good coverage of the 
PTV and good sparing of organs at risk, including the bones. 
This treatment method, including the prescription dose and 
treatment duration, will be needed further research. 
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Purpose or Objective: After more than 30 years, Ipilimumab 
was the first agent which showed a survival benefit for the 
treatment of metastatic melanoma. However, only about the 
20% of patients have a long-term survival benefit. The 
combination of ipilimumab with other therapies might 
improve its efficacy. Abscopal effect refers to a regression of 
metastatic lesions distant from the primary site of 
radiotherapy (RT). This systemic response is observed in 
patients who received ipilimumab. Here we reported the 
outcomes from patients treated in the ipilimumab Italian 
expanded access program (EAP) who received RT after 
ipilimumab progression. 
 
Material and Methods: Patients with advanced melanoma 
who had received RT after ipilimumab progression were 
eligible for analysis. Radiotherapy was available upon 
physician request for patients who failed ipilimumab therapy 
and for whom no other therapeutic options were available. 
 
Results: 21 out of 95 patients treated with ipilimumab in the 
Italian EAP were eligible for the analysis. The median age 
was of 58 years (range 21-77); the progression free survival 
(PFS) from ipilimumab treatment was 4 months (range 3-6), 
while the time from the end of treatment with ipilimumab 
and RT was of 5 months (range 4-8). RT was performed on 
brain in 13 patients: 8 were treated with whole-brain RT and 
5 patients with stereotactic RT. Other RT treatment included 
bone, metastatic distant lymph nodes, sub-cutaneous 
metastasis, spinal cord metastatis. The median doses was 30 
Gy (range 30-50). A local response to RT was detected in 13 
patients while 8 patients did not show any local regression. 
The abscopal response has been detected in 11/21 patients: 
in details, we observed 9 abscopal partial response , 2 
abscopal stable disease , and 10 progression . The median of 
occurrence of the abscopal response was of 1 month (range 
1-4). The median overall survival (OS) for all the 21 patients 
was of 13 months (range 6-26). The median OS for patients 
